anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The investigators will use a novel cluster randomized unbalanced crossover trial design. When a new site is enrolled, the first approximately 6 months of the project will be a "ramp-up" period during which the protocol will be re-reviewed during a site visit to the participating EDs and random block assignments will be generated and delivered. The last 6 months will be reserved for data analysis, study closeout, and manuscript preparation. An intervening 2-year period will be divided into 4 six-month calendar time periods for carrying out the protocol and data collection. For each 6-month period, each ED will have a randomized treatment assignment for pediatric emergency and critical care consultations ("M" for telemedicine and "P" for telephone.) Participating EDs (the unit of randomization) will be stratified into two strata by size of ED and geographical location. EDs will then be randomized within-strata to one of the four unbalanced (3:1) crossover treatment assignment sequences, each consisting of a 6-month period: PMMM, MPMM, MMPM, or MMMP. During these assigned periods, the type of consultation being assigned will be strongly encouraged, but deviating from protocol (i.e., using telephone consultation when randomized to telemedicine, or the vice-versa) will be allowed as needed by the physicians. Data will be collected and abstracted through retrospective chart review.
Hepatocellular carcinoma (HCC) is the most common type of liver cancer. Most patients with HCC are diagnosed as advanced stage or unresectable disease because of the lack of signs and symptoms. Despite significant research efforts, only a few effective treatment approaches have been developed for HCC. Conventional transarterial chemoembolization (cTACE) is widely used as a palliative treatment for inoperable HCC. TACE based on drug-eluting beads (DEB-TACE) has recently been introduced into the clinic. This technique relies on drug-loaded microspheres to embolize and release antitumor medication gradually and locally in order to maximize local ischemia and tumor necrosis. Nowadays, many RCTs and meta-analyses found DEB-TACE is associated with higher overall survival than cTACE for unresectable HCC. However, the long-term survival is still low after DEB-TACE treatment. In recent years, targeted drugs (such as sorafenib, lenvatinib) and immune checkpoint inhibitor (anti-PD-1) have exhibited potential therapeutic effects for advanced HCC. Lenvatinib is non-inferior to sorafenib in overall survival in untreated advanced HCC. Combining targeted drugs or immunotherapies with conventional therapeutic approaches may provide synergistic effects and facilitate the development of personalized medicine. However, it is still unknown which is the best combining treatment. Therefore, this prospective study aims to investigate the safety and efficacy of DEB-TACE plus sorafenib or lenvatinib or PD-1 Inhibitor for unresectable HCC.
In the United States, there is an epidemic of obesity and, as a result, an epidemic of diabetes. Obese individuals with pre-diabetes (defined as impaired fasting glucose or impaired glucose tolerance) are at high risk for progression to diabetes. A vast majority of these individuals also have an increased risk of cardiovascular disease because of concomitant risk factors, such as abdominal obesity, dyslipidemia, and elevated blood pressure. Intensive lifestyle interventions that focus on dietary change, physical activity, and behavior modification have demonstrated efficacy in achieving and maintaining clinically significant (\>5%) weight loss in populations of patients with pre-diabetes. However, the effectiveness, cost-effectiveness, generalizability, and sustainability of such interventions in routine primary care settings remain unknown, and rigorous clinical research is needed.

The primary hypothesis for the E-LITE Study is that the CM intervention will reduce BMI more than the SM intervention, which in turn will reduce BMI more than usual care, over 15 months. Secondarily, we hypothesize that, compared with usual care, intervention participants will be associated with greater improvements in waist circumference, lipids, blood pressure, blood glucose, lifestyle behaviors, and psychosocial well-being. In addition, we will examine the durability of weight loss and behavioral change in the months after the initial 3-month intensive stage.
Muscular responses to resistance training vary extensively between humans, with many showing impaired growth. In such individuals, cellular plasticity is compromised, leading to reduced functional and health-beneficial outcomes of training. While this is likely due to a range of determinants, including epigenetic, genetic and physiological variables, recent studies suggest that it involves reduced ability to produce novel ribosomes in response to training. This eventually leads to less pronounced increases in protein synthesis, and thus decreased growth rates, and makes ribosomal content in muscle a potential proxy marker for training-associated muscle hypertrophy.

In a recent study, the investigators showed that increased resistance training volume was associated with more pronounced muscle growth, a trait that was associated with increased ribosomal biogenesis. Despite this, \~50 % of the participants did not exhibit true beneficial effects of increased training volume, which in turn coincided with reduced abilities to accumulate ribosomes. In such individuals, other means are likely necessary to circumvent the negative influence of genetic and epigenetic predispositions on muscle plasticity. Nutrient supplementation stand out as a potential therapy. However, at present, knowledge with regard to this perspective is limited to a selected few nutrients, with protein ingestion being the best studied potential adjuvant, for which adequate intake seems to be essential for achieving optimal muscle growth, potentially being interconnected with ribosomal synthesis. For other nutrients, such as glucose, little is know about their importance for muscle plasticity and ribosomal biogenesis.

In cell types such as cultivated kidney cells, exposure to high levels of glucose is an efficient mean to increase ribosomal biogenesis (and growth rates). This suggests that glucose is an important signaling molecule for increasing ribosomal production per se, perhaps acting as a ligand for signaling proteins or by acting to increase energy availability. In the human body (as opposed to cultured cells), glucose may also exert growth-stimulating effects by increasing insulin levels in blood. Overall, it thus seems plausible that glucose intake during resistance training may stimulate ribosomal biogenesis, in turn having beneficial effects for protein synthesis and muscle plasticity, perhaps acting in an additive manner to protein supplementation. At present, we do not know if this is the case, though studies have suggested that glucose ingestion during acute resistance training sessions may reduce training-induced muscle damage without affecting within-session work output (i.e. volume). This lack of knowledge is surprising given the long-standing appreciation of the beneficial effects of glucose intake for endurance performance, acting to delay muscular fatigue.
The investigator propose an innovative approach to solving the clinical problem at hand, the lack of identified measurable parameters one can use to predict the risk of future metabolic disease in women diagnosed with PCOS.The chosen approach is the standardised collection of phenome and metabolome data and their unbiased integration by machine learning analysis. Utilising the detailed results of the clinical phenome and metabolome analysis in the DAISy-PCOS Phenome Study cohort, The study will aim to identify distinct subsets (=clusters) of PCOS patients that share similar characteristics. This approach has previously been used by the team to successfully identify distinct steroid markers that can serve as a "malignant steroid fingerprint" in urine to distinguish benign from malignant tumours in patients with incidentally discovered adrenal masses. Similarly, The investigator have used unbiased analysis of steroid metabolome data to reveal that patients with aldosterone excess also overproduce glucocorticoids and that the latter explains the majority of metabolic disease risk observed in affected patients.

In the integrated analysis of the DAISy-PCOS phenome and metabolome data, The investigator will apply a variety of methods in the context of connectivity or centroid-based clustering and density estimation. Supervised relevance learning will give insight into markers, e.g. steroids, that are most decisive for the determination of cluster memberships. In addition, The investigator will use state-of-the-art visualisation and machine learning techniques based on adaptive similarity measures.the investigator will use integrative approaches, addressing the heterogeneous data from different sources as a whole, whilst considering data-driven adaptation of generative models for the underlying biological processes. The investigator will employ these approaches to characterise central phenotype clusters affecting large numbers of patients as the basis of personalised management including outcome prediction.
Abstract The present disclosure provides inter alia compositions that comprise therapeutic agents (e.g., live attenuated viral antigens, therapeutic proteins, etc.) and a lipid component. The lipid component may comprise or consist of different types of lipid or lipids as described herein. In some embodiments the therapeutic agents are thermolabile. The present disclosure also provides methods for preparing compositions, including the aforementioned compositions (e.g., melt methods and spray injection methods among others). 9770469_1 (GHMattem) P97653.AU.1
An apparatus and a method for continuously manufacturing moisture films are revealed. At least one loading surface formed by a belt conveyor is used to support and move a lower fabric layer synchronously. During the movement, a top surface of the lower fabric layer is coated with a first fixing solution layer, a gel layer and a second fixing solution layer so as to form a film gradually. Moreover, an upper fabric layer is provided to be attached over the gel layer correspondingly. Then the second fixing solution layer is coated over the upper fabric layer. Thereby a continuous manufacturing of moisture films with or without carriers is completed.
Transcutaneous electrical nerve stimulation (TENS) activates various pathways to induce antinociceptive effects, based on the frequencies used. This study evaluates the preemptive analgesic effects and their duration of low- (LT: 4 Hz) and high-frequency TENS (HT: 100 Hz) using a rat model of acute inflammatory pain. Acute inflammation was induced by injecting 1% formalin into the hind paws of rats. LT or HT was applied for 30 min before formalin injection. Pain-related behaviors, such as licking, flinching, and lifting, were recorded for 60 min postinjection. Immunohistochemistry was used to assess the number of phosphorylated extracellular signal-regulated kinase (pERK)- and c-fos-positive cells in the spinal cord. Naloxone, a μ-opioid receptors (MORs) antagonist, and naltrindole, a δ-opioid receptors (DORs) antagonist, were administered before TENS application. Pain behavior duration and pERK- and c-fos-positive cell expression were then measured. LT and HT pretreatment significantly reduced both pain behaviors and the number of pERK- and c-fos-positive cells postformalin injection. Naloxone and naltrindole partially reversed the effects of LT and HT, respectively. Notably, HT's analgesic effect lasted up to 120 min whereas that of LT persisted for 90 min. LT and HT effectively exerted their preemptive analgesic effects on acute inflammatory pain by inhibiting pERK and c-fos expression in the spinal cord. HT presented a longer-lasting effect compared to LT. MOR and DOR activation may contribute to LT and HT's analgesic mechanisms, respectively.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to pediatric surgery and burn injury medicine, and can be used for complex treatment of enteral insufficiency in children with severe thermal trauma. That is ensured by intubation of proximal gastrointestinal tract from the day of hospital admission to the background of standard treatment in the acute period of burn disease. Then enterosorbent "Polysorb MP" is introduced in amount of 0.1 gram per 1 kg of patient's body weight 4 times a day. Prior to introduction, the calculated dose of the preparation is dissolved in drinking water. In the period of burn shock, the preparation is introduced through a nasogastric tube followed by oral introduction of the preparation. Enterosorption is followed by daily sessions of intravenous laser irradiation of blood with an ALT "Matrix-VLOK" device at wave length 635 nm, power 4.0 mW for 20 minutes. Therapeutic course is 10 days from the day of hospital admission.EFFECT: method provides restoration of function of gastrointestinal organs, prevention of developing intestinal insufficiency syndrome and its complications, reduced level of endogenous intoxication, unloading of detoxification organs in children with severe thermal trauma.1 cl, 1 tbl, 5 dwg, 1 ex
PURPOSE: A composition containing flavonoid for treating leukemia is provided to ensure strong effect for a patient with imatinib resistance. CONSTITUTION: A composition for treating leukemia contains 3-hydroxyflavone compounds as an active ingredient. The compound is analog or homolog of 3-hydroxyflavone compound. The composition additionally contains imatinib mesylate. A composition for treating imatinib resistant leukemia contains 3-hydroxyflavone compounds as an active ingredient and imatinib mesylate. A composition for treating anti-cancer drug resistant cancer contains 3-hydroxyflavone as an active ingredient.
Participants first received placebo tablets (matching PES) for 10 days. Placebo was taken 6 times daily with gluten-free meals and snacks. To facilitate duodenal digestion Omeprazole (20 mg/QD) was co-administered. After a washout period of 1 week, they then received PES tablets six times daily for 10 days.
This cohort comprises approximately 50 historical controls who received either whole genome sequencing (WGS) or standard diagnostic testing as part of their participation in a previous version of this protocol, which used a randomized controlled design to assess diagnostic efficacy of WGS. This cohort is closed to new enrollment, and exists for statistical analysis purposes only.
<P>PROBLEM TO BE SOLVED: To provide an antagonist for melanin-concentrating hormone (MCH) for treating obesity.  <P>SOLUTION: There are disclosed compounds of formulas (I) and (II), which are new antagonists for melanin-concentrating hormone (MCH), as well as a method for preparing the compounds. In another embodiment, there are provided not only a pharmaceutical composition including the MCH antagonists as well as a method for using thereof to treat obesity, metabolic disorders, eating disorders (e.g. hyperphagia), and diabetes. The pharmaceutical composition includes an obesity treating amount of the compound of formula I or II, or a pharmaceutically acceptable salt of the compound, and a pharmaceutically acceptable carrier therefor.  <P>COPYRIGHT: (C)2010,JPO&INPIT
<P>PROBLEM TO BE SOLVED: To provide a method for efficiently extracting/collecting antioxidative components contained in cell walls through cutting the high molecular structure of plant cells with hydrolysis of a plant raw material under saturated vapor at heating temperature without using hot water in a subcritical water area.  <P>SOLUTION: This method for extracting/collecting the antioxidative components contained in cell walls comprises raw material charging treatment, hydrolyzing treatment and cooling treatment. The raw material charging treatment comprises charging a plant raw material containing the antioxidative components in cell walls into a treatment chamber and sealing the treatment chamber. The hydrolyzing treatment comprises heating the plant raw material in the treatment chamber at 130-150°C, and breaking the cell walls of the plant raw material through exposing the plant raw material for a fixed time in steam atmosphere of water contained in the plant raw material, and releasing the antioxidative components contained in cell walls from cell walls followed by taking into steam containing plant cell components taken out by destruction of cell walls. The cooling treatment comprises performing hydrolyzing treatment and extracting the antioxidative components contained in steam through cooling steam in the treatment chamber.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The aim of this study is to investigate whether placement of a 3G dialing mobile phone causes direct changes in EEG activity compared to the placement of a sham phone. Furthermore, it is investigated whether placement of the mobile phone on the ear or the heart results in different outcomes. The subjects are measured twice: on one of the two days the mobile phone is attached to the ear, the other day to the chest. In this single-blind, cross-over design, assessments in the sham phone conditions are conducted directly preceding and following the mobile phone exposure. During each assessment, EEG activity and radiofrequency radiation are recorded jointly. Delta, theta, alpha, slowbeta, fastbeta, and gamma activity are computed. The association between radiation exposure and the EEG is tested using multilevel random regression analyses with radiation as predictor of main interest.
The last 12 patients will all have the device placed on their eye. They will then be randomized in a 2:1 ratio to receive either an injection of ethacrynic acid or balanced salt solution.
Previously at St. Jude Children's Research Hospital, monitoring and reporting of late treatment sequelae developing in protocol participants have occurred at the discretion of individual investigators. A formal mechanism for coordinating long-term follow-up data collection of late cancer-related toxicity did not exist within the institution, nor did a central data repository to facilitate correlation of clinical and treatment factors predisposing to toxicity. Central coordination of late effects monitoring and reporting at St. Jude offers the potential benefit of facilitating timely communication about life-threatening or unanticipated late toxicity to investigators developing contemporary therapeutic studies and monitoring predisposed survivors who may benefit from preventive or corrective interventions.

This study centralizes the late effects monitoring and reporting of St. Jude therapeutic studies which have been completed under the auspices of one umbrella protocol. This protocol is not an independent research study, but rather a means to aggregate outcome and late effects reporting regarding all patients actively being treated and previously treated at St. Jude Children's Research Hospital for the diagnosis of childhood cancer. Data collected on the patient will include only those data obtained through clinical staff or Cancer Registry encounters that are documented in the medical record or provided by the patient or family on follow-up forms. All monitored patients will have information provided regarding status (alive/expired), relapse, subsequent malignancies, and death for any cause. Clinical outcomes, toxicity and late effects monitoring planned in the study on which the patient was originally enrolled will be collected by the principal investigators of that study. Subjects will then be followed in the After Completion of Therapy on an annual basis for 10 years from diagnosis (or 10 years from completion of salvage therapy for relapse) or until they are at least 18 years of age. They will undergo specific screening laboratory, diagnostic imaging studies, and subspecialty consultations as medically indicated by predisposing cancer treatment exposures. At the time of discharge from ACT clinic the subject will begin annual lifetime follow-up by the St. Jude Cancer Registry.
Participants will take tablets of asciminib by mouth every day on this study. Participants should take it at least 1 hour before and 2 hours after eating. The tablets should be swallowed whole, not crushed.
Objective: The central nervous system is known to have asymmetric immune system modulation. Thus far, no clinical study has examined asymmetric immune modulation between hemispheres in focal epilepsy patients. We aimed to compare the prognosis of epilepsy patients lateralized to the right hemisphere with epilepsy patients lateralized to the left hemisphere using clinic and demographic data.Method: Ninety-nine patients with focal epilepsy with all seizures originating in only one hemisphere, between the ages of 18-and 86 years were included. We included patients with focal epilepsy whose seizures were lateralized to only one hemisphere. Age, gender, marital status, education, mental retardation, hand dominance, etiology, trauma, central nervous system infection, febrile convulsion, parental relationships, seizure onset age, seizure frequency (per month), systemic disease, and biochemical parameters were recorded. To evaluate lateralization, we used positron emission tomography (PET/CT), long-term video-electroencephalography (EEG), and magnetic resonance imaging (MRI) investigations.Results: Thirty-seven patients (37.4%) patients were right-lateralized, whereas 62 patients (62.6%) were left-lateralized (p = 0.01). Seizures frequency seizures were higher in patients lateralized to the left hemisphere than in the right. (p = 0.001). In patients with epilepsy lateralized to the left hemisphere, epilepsy onset age was lower (p = 0.003), numbers of antiepileptic medicines were higher (p = 0.04), and epilepsy durations and longest seizure-free periods were longer (p = 0.001 and p = 0.04, respectively).Conclusion: We have shown that compared to the right hemisphere, the left hemisphere is far more prone to seizures and has a poorer prognosis.
Participants will receive MK-6070 once weekly (Q1W) via intravenous (IV) infusion during each 21-day cycle. Dose escalation may continue until one or more RDEs are identified, participant discontinuation or the Sponsor decides to stop enrollment.
PURPOSE:To provide an antiinfectant having an antiinfective action, useful for viral diseases and causing no adverse reaction, by containing the alkaline water extract of pine tree seed shells. CONSTITUTION:The seed shells of a pine tree such as black pine tree, red pine tree or GOYOMATSU (a five leaves pine tree), preferably the shells of the edible seeds of the GOYOMATSU, are extracted with an alkaline water such as ammonia water at ordinary or high temperature, followed by performing the filtration, concentration and drying of the extract to provide a powder. The objective agent contains the powder as an active ingredient and is obtained by compounding the powder with a carrier for preparations and subsequently preparing the composition by a conventional method. The agent can be prepared in a shape of tables, granules, powders, injections, etc. The powder of the active ingredient has a slightly characteristic smell and is readily soluble in water and brown. The alkaline water for the extraction is preferably used under a pH of >=7 in an amount of approximately five times that of the seed shell of the pine tree.